Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

73.18 -1.88 (-2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 581,110
Open 74.57
Bid (Size) 72.01 (2,200)
Ask (Size) 75.00 (100)
Prev. Close 75.06
Today's Range 73.18 - 76.00
52wk Range 6.480 - 77.00
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Deadline Approaching: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire

Performance

YTD
+68.5%
+68.5%
1 Month
-0.9%
-0.9%
3 Month
+61.1%
+61.1%
6 Month
+43.3%
+43.3%
1 Year
+454.3%
+454.3%

More News

Read More
News headline image
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q4 2025 Earnings: Revenue Surges 105% Above Estimates ↗
Via Chartmill
News headline image
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Law Offices of Howard G. Smith Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Nektar (NKTR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Nektar Therapeutics (NKTR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims
From Grabar Law Office
Via GlobeNewswire
News headline image
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR
From DJS Law Group
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Frequently Asked Questions

Is Nektar Therapeutics - Common Stock publicly traded?
Yes, Nektar Therapeutics - Common Stock is publicly traded.
What exchange does Nektar Therapeutics - Common Stock trade on?
Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nektar Therapeutics - Common Stock?
The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market
What is the current price of Nektar Therapeutics - Common Stock?
The current price of Nektar Therapeutics - Common Stock is 73.18
When was Nektar Therapeutics - Common Stock last traded?
The last trade of Nektar Therapeutics - Common Stock was at 03/18/26 04:00 PM ET
What is the market capitalization of Nektar Therapeutics - Common Stock?
The market capitalization of Nektar Therapeutics - Common Stock is 13.45B
How many shares of Nektar Therapeutics - Common Stock are outstanding?
Nektar Therapeutics - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.